Accenture and Bristol-Myers Squibb launched the pharmaceutical industry’s first-ever joint centre for pharmacovigilance in Chennai as India has lower costs, easily available skilled pool of manpower and the advantage of time difference with the West.

Accenture and Bristol-Myers Squibb Company launched, the pharmaceutical industry's first joint center for pharmacovigilance in Chennai, India. Pharmacovigilance is the monitoring of safety data to ensure optimal use of medicines. It entails the capture, assessment, and reporting of potential side effects to medicines.

Pharmacovigilance is the science relating to the detection, assessment, understanding and prevention of adverse effects of medicines. A pharmacovigilance centre processes and codifies adverse event data and generates regulatory periodic and aggregate reports on safety.

Accenture is a global management consulting, technology services and outsourcing company. Committed to delivering innovation, Accenture collaborates with its clients to help them become high-performance businesses and governments. Operated by more than 140 Accenture employees, the new center will undertake the processing and coding of adverse event data and the generation of regulatory periodic and aggregate reports on safety as well as physician medical review of adverse events.

This is the first time a collaboration for 'end-to-end' safety case processing has been established and is inclusive of specialized activities, such as medical review of the reported adverse reactions. The team is organized as a parallel process and extension of the Bristol-Myers Squibb pharmacovigilance headquarters' operations. It allows for the seamless handling of data and reports between Accenture and Bristol-Myers Squibb while not compromising patient safety.

John Balian, M.D., senior vice president, Global Pharmacovigilance and Epidemiology, Bristol-Myers Squibb  said that building a joint team with a specialized focus will support the continued growth of the company’s  robust product pipeline, improving scalability and increasing overall productivity and  will continue to access world-class talent to deliver on our regulatory obligations, while enhancing our focus on patient safety

Eric Sandor, managing director of Accenture Pharmacovigilance Services said that the leading companies are re-thinking their operating model to drive sustainable growth and productivity.

 The pharmacovigilance center is part of Accenture's Life Sciences Centers of Excellence in Bangalore and Chennai that Bristol-Myers Squibb already utilizes. Part of the multi-year R&D agreement signed in April this year, the pharmacovigilance center furthers Bristol-Myers Squibb's efforts to significantly expand its R&D capabilities in India as an integral part of the company's overall global strategy.